VISTA is also known to be upregulated on tumor cells in cancers such as mesothelioma, ovarian cancer, gastric cancer, and NSCLC43–46, and upregulated in prostate cancer upon treatment with anti-CTLA4 antibody8. This evidence concerns the gene CTLA4 and prostate carcinoma.